Net sales were 57.6 hundred million yen (Year-over-Year +12.1%), operating income was 6.8 hundred million yen (YoY +14.5%), marking the highest first-half on record. By segment, Laboratory, Industry and Medical performed strongly. Full-year forecasts were revised upward to net sales 120,870 million yen and operating income 13,750 million yen. Measures were taken to address cost fluctuations due to Middle East conditions. Some costs related to the new center were recorded.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7476","jir_company_name":"AS ONE Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/7476-20261030-02.pdf","jir_short_summary":"Net sales were 57.6 hundred million yen (Year-over-Year +12.1%), operating income was 6.8 hundred million yen (YoY +14.5%), marking the highest first-half on record. By segment, Laboratory, Industry and Medical performed strongly. Full-year forecasts were revised upward to net sales 120,870 million yen and operating income 13,750 million yen. Measures were taken to address cost fluctuations due to Middle East conditions. Some costs related to the new center were recorded.","jir_summary":"### Summary of Performance\nFor 2Q of this fiscal year, consolidated net sales were 57.6 hundred million yen, an increase of +12.1% year-over-year, recording the highest first-half on record. Operating income was 6.8 hundred million yen, up +14.5% year-over-year. Gross profit margin was 30.5%, roughly in line with the prior year. By segment, demand expansion in Laboratory, Industry and Medical contributed. Efforts continue to absorb cost fluctuations caused by Middle East conditions through surcharges and other measures. Full-year outlook has been revised upward to net sales of 120,870 million yen and operating income of 13,750 million yen.\n\n### Outlook and Impact for Investors\nWith solid R&D investment and AI-related investment in the first half, the Laboratory and Industry divisions are expected to remain firm in the second half. The Medical division is conservatively forecasted due to revisions to medical fee schedules, but improvement is anticipated. Attention is required regarding raw material cost fluctuations from Middle East conditions; however, gross margin is expected to stabilize through cost updates and expansion of proprietary products. Costs related to rental and calibration centers are progressing as planned.","jir_financial_highlights":"Net Sales: 57.6 hundred million yen (Year-over-Year +12.1%)\nOperating Income: 6.8 hundred million yen (Year-over-Year +14.5%)\nConsolidated Interim Net Income: 4,726 million yen (Year-over-Year +9.2%)\nNet Sales (Full Year): 120,870 million yen (vs Initial Plan +2.6%)\nOperating Income (Full Year): 13,750 million yen (vs Initial Plan +6.6%)\nSales by Segment: Laboratory 69,387 million yen, Industry 23,798 million yen, Medical 16,925 million yen (Downside\/upswing factors expected in the second half)","jir_category":"","jir_hashtags":"#ASONE, #Earnings, #BusinessSegments, #MidtermPlan","jir_key_figures":"Net Sales (2Q Results): 57.6 hundred million yen\nOperating Income (2Q Results): 6.8 hundred million yen\nNet Sales (Full Year Outlook): 120,870 million yen\nOperating Income (Full Year Outlook): 13,750 million yen\nInterim Net Income: 4,726 million yen","jir_meta_title":"AS ONE Corporation Supplementary Financial Materials: 2Q Results and Full-Year Outlook | Fiscal 2026","jir_meta_description":"AS ONE Corporation 2Q supplementary financial materials for fiscal 2026. Net sales 57.6 hundred million yen (+12.1%), operating income 6.8 hundred million yen (+14.5%). Full-year outlook: net sales 120,870 million yen and operating income 13,750 million yen. Analysis of segment trends and cost developments.","jir_og_title":"AS ONE Corporation Supplementary Financial Materials: 2Q Results & Full-Year Outlook","jir_og_description":"2Q results: net sales 57.6 hundred million yen, operating income 6.8 hundred million yen. Full-year outlook revised upward to net sales 120,870 million yen and operating income 13,750 million yen. Analysis of segment trends and cost movements.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Sales by Segment\", \"jir_chart_json_data\": \"{}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Gross Margin Trend\", \"jir_chart_json_data\": \"{}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Forecast and Results\", \"jir_chart_json_data\": \"{}\"}]","ir_related_company":9038,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138744","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n